ALEXANDRIA, Va., Aug. 12 -- United States Patent no. 12,385,061, issued on Aug. 12, was assigned to Poseida Therapeutics Inc. (San Diego).

"Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression" was invented by Eric M. Ostertag (San Diego) and Devon Shedlock (San Diego).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed are composition comprising (a) an inducible transgene construct, comprising a sequence encoding an inducible promoter and a sequence encoding a transgene, and (b) a receptor construct, comprising a sequence encoding a constitutive promoter and a sequence encoding an exogenous receptor, wherein, upon integration of the construct of (a) and the co...